The implant mimics the natural motion of a native disc and is indicated as an alternative to cervical fusion. It received FDA approval in 2019 and also has a CE mark in the European union.
Earlier this year, three- and four- year data showed the effectiveness of M6-C at the single level, and a U.S. investigational device exemption two-level study began in August.
“The M6-C artificial cervical disc is continuing to establish a market-leading position globally with more than 60,000 devices implanted worldwide,” Orthofix President of Global Spine Kevin Kenny stated in a news release from the company. “We are pleased to see the continued adoption of this state-of-the-art technology as our international success translates into the U.S. market.”
